Projects per year
Abstract
A higher total cell-free DNA (cfDNA) level is a poor prognosticator in advanced prostate cancer patients receiving novel hormonal therapies. Additionally, an early on-treatment rise in cfDNA levels predicts for better outcomes. Therefore, total cfDNA concentration may assist in prognostication and predicting treatment outcome.
Original language | English |
---|---|
Pages (from-to) | 1287-1291 |
Number of pages | 5 |
Journal | European Urology Focus |
DOIs | |
Publication status | Published - Nov 2021 |
Keywords
- Abiraterone
- Androgen receptor pathway inhibitor
- Biomarker
- Castrate resistant
- Cell-free DNA
- Enzalutamide
- Liquid biopsy
- Prostate cancer
-
-
NHMRC Practitioner Fellowship
National Health and Medical Research Council (NHMRC) (Australia)
1/01/16 → 31/12/20
Project: Other